This work, and that of colleagues Brian Druker and Novartis, led to the development of the kinase inhibitor imatinib (Gleevec) as primary therapy for chronic myelogenous leukemia (CML), and the discovery that imatinib resistance is caused by BCR - ABL kinase domain mutations. (thecolumngroup.com)
A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS / MPN Patients Who Fail Primary Therapy with DNA Methyl Transferase Inhibitors (vicc.org)
The University of Michigan C.S. Mott Children's Hospital Pediatric Oncology Program has an active research program in pediatric neuroblastoma, with several novel protocols developed for the treatment of patients who have failed primary therapy. (mottchildren.org)